Q-omics provides the consensus-scored SLC35A2 profile across patient tissues and cancer cell-line models. SLC35A2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SLC35A2 is differentially expressed in 17, with the highest sampling consensus in BLCA. Additionally, SLC35A2 protein abundance shows 26,044 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight UVM, BLCA, and PDAC as cancer lineages where SLC35A2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC35A2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC35A2 survival associations across molecular data types. SLC35A2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC35A2 RNA expression–survival associations across cancer types. High SLC35A2 expression shows unfavorable associations in UVM, BRCA, KIRP, COAD, LGG and LIHC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for SLC35A2 RNA expression.
This table summarizes SLC35A2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 10. The strongest signals are observed in BLCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SLC35A2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC35A2 shows higher tumor expression in BLCA, COAD, HNSC, LUAD, LIHC and STAD. The BLCA box plot shows higher SLC35A2 RNA expression in tumor versus normal tissue (log2 FC = +1.724, t-test p < 0.001).
This table shows molecular features associated with SLC35A2 in patient tissues and cancer cell lines. In patient samples, SLC35A2 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC35A2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and SOFT_TISSUE.
